SpringWorks Therapeutics Stock Sees RS Rating Jump To 86

Blockhead

01-14

On Monday, SpringWorks Therapeutics (SWTX) stock hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 86, up from 77 the day before.

↑ X NOW PLAYING This Is How 2025 Jobs Reports Will Impact The Fed And Rate Cuts

This proprietary rating measures technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.

Decades of market research reveals that the market's biggest winners typically have an 80 or higher RS Rating as they launch their biggest price moves.

Looking For The Best Stocks To Buy And Watch? Start Here

Is SpringWorks Therapeutics Stock A Buy?

SpringWorks Therapeutics stock is working on a cup without handle with a 53.92 entry. See if the biotech stock can clear the breakout price in volume at least 40% above average.

The biotech company reported 0% earnings growth in its most recent report, while sales growth came in at 0%.

SpringWorks Therapeutics stock holds the No. 46 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals (CPRX), ADMA Biologics (ADMA) and Exelixis (EXEL) are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."

YOU MAY ALSO LIKE:

Learn How To Time The Market With IBD's ETF Market Strategy

Find Today's Best Growth Stocks To Watch With IBD 50

Find The Best Long-Term Investments With IBD Long-Term Leaders

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503537043"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503537043\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503537043?lang=zh_CN&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2017/05/IRU4-150x150.jpg","is_english":true,"pubTime":"2025-01-14 03:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503537043","market":"fut","top_or_hot":-1,"title":"SpringWorks Therapeutics Stock Sees RS Rating Jump To 86","media":"Blockhead","content":"<html><body><div>\n<p>On Monday, <b>SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></b> (SWTX) stock hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 86, up from 77 the day before.</p>\n<span>\n<span>\n<span jw-video-key=\"P60da92U\" vid-authors=\"MEREDITH HEYMAN\" vid-cat=\"Industry Insights\" vid-date=\"01/02/2025\" vid-date-tmsp=\"1735802129\" vid-dom-id=\"9599934-6785702700bcc\" vid-id=\"9599934\" vid-image=\"https://www.investors.com/wp-content/uploads/2024/12/P60da92U-640x360.jpg\" vid-name=\"This Is How 2025 Jobs Reports Will Impact The Fed And Rate Cuts\" vid-repeat=\"1\" vid-top=\"\" vid-url=\"https://content.jwplatform.com/manifests/P60da92U.m3u8\" vid-width=\"50\">\n<span>↑</span>\n<span>X</span>\n<span>\n<span>NOW PLAYING</span>\n<span>This Is How 2025 Jobs Reports Will Impact The Fed And Rate Cuts</span>\n</span>\n</span>\n</span>\n</span>\n<p>This proprietary rating measures technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.</p>\n<p>Decades of market research reveals that the market's biggest winners typically have an 80 or higher RS Rating as they launch their biggest price moves.</p>\n<hr/>\n<p>Looking For The Best Stocks To Buy And Watch? Start Here</p>\n<hr/>\n<h2>Is SpringWorks Therapeutics Stock A Buy?</h2>\n<p>SpringWorks Therapeutics stock is working on a cup without handle with a 53.92 entry. See if the biotech stock can clear the breakout price in volume at least 40% above average.</p>\n<div><div></div></div>\n<p>The biotech company reported 0% earnings growth in its most recent report, while sales growth came in at 0%.</p>\n<p>SpringWorks Therapeutics stock holds the No. 46 rank among its peers in the Medical-Biomed/Biotech industry group. <b>Catalyst Pharmaceuticals</b> (CPRX), <b>ADMA Biologics</b> (ADMA) and <b>Exelixis</b> (EXEL) are among the top 5 highly rated stocks within the group. For more industry news, check out \"Biotech And Pharmaceutical Industry And Stock News.\"</p>\n<p><strong>YOU MAY ALSO LIKE:</strong></p>\n<p><span>Learn How To Time The Market With IBD's ETF Market Strategy</span></p>\n<p><span>Find Today's Best Growth Stocks To Watch With IBD 50</span></p>\n<p><span>Find The Best Long-Term Investments With IBD Long-Term Leaders</span></p>\n<p><span>How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks</span></p>\n</div></body></html>","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SpringWorks Therapeutics Stock Sees RS Rating Jump To 86</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpringWorks Therapeutics Stock Sees RS Rating Jump To 86\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-14 03:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/springworks-therapeutics-stock-sees-rs-rating-jump-to-86/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Monday, SpringWorks Therapeutics (SWTX) stock hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 86, up from 77 ...</p>\n\n<a href=\"https://www.investors.com/news/springworks-therapeutics-stock-sees-rs-rating-jump-to-86/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.investors.com/news/springworks-therapeutics-stock-sees-rs-rating-jump-to-86/","article_id":"2503537043","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/05/IRU4-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503537043","pubTimestamp":1736797620,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"SpringWorks Therapeutics sees its Relative Strength Rating hit the 80-plus level.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"SpringWorks Therapeutics股票RS评级跃升至86","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"RS":1},"content_text":"On Monday, SpringWorks Therapeutics (SWTX) stock hit an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 86, up from 77 the day before.\n\n\n\n↑\nX\n\nNOW PLAYING\nThis Is How 2025 Jobs Reports Will Impact The Fed And Rate Cuts\n\n\n\n\nThis proprietary rating measures technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.\nDecades of market research reveals that the market's biggest winners typically have an 80 or higher RS Rating as they launch their biggest price moves.\n\nLooking For The Best Stocks To Buy And Watch? Start Here\n\nIs SpringWorks Therapeutics Stock A Buy?\nSpringWorks Therapeutics stock is working on a cup without handle with a 53.92 entry. See if the biotech stock can clear the breakout price in volume at least 40% above average.\n\nThe biotech company reported 0% earnings growth in its most recent report, while sales growth came in at 0%.\nSpringWorks Therapeutics stock holds the No. 46 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals (CPRX), ADMA Biologics (ADMA) and Exelixis (EXEL) are among the top 5 highly rated stocks within the group. For more industry news, check out \"Biotech And Pharmaceutical Industry And Stock News.\"\nYOU MAY ALSO LIKE:\nLearn How To Time The Market With IBD's ETF Market Strategy\nFind Today's Best Growth Stocks To Watch With IBD 50\nFind The Best Long-Term Investments With IBD Long-Term Leaders\nHow To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}